Castle Biosciences, Inc. (CSTL)
| Market Cap | 1.74B |
| Revenue (ttm) | 68.04M |
| Net Income (ttm) | -15.13M |
| Shares Out | 25.06M |
| EPS (ttm) | -0.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $69.18 |
| Previous Close | $68.65 |
| Change ($) | 0.53 |
| Change (%) | 0.77% |
| Day's Open | 68.68 |
| Day's Range | 66.15 - 70.31 |
| Day's Volume | 20,137 |
| 52-Week Range | 36.15 - 107.69 |
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences announced that it will release its financial results for the second quarter and six months ended June 30, 2021 on Aug...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AHNS--Castle Biosciences announced a podium presentation at the American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SDPA--Castle Biosciences announced data presentations at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #boardofdirectors--Castle announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CHRON100--Castle has been included in the Houston Chronicle's list of the 100 most successful publicly traded companies in the Houston area.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxSCC--Castle announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BairdESGConference--Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatm...
SAN DIEGO, May 26, 2021 /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has a...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #headquarters--Castle today announced it will host a ribbon cutting ceremony at its new corporate headquarters.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanSkinAssociation--Castle today announced its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert p...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #OpcoMedTech2021--Castle today announced that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BoardofDirectors--Castle today announced that Tiffany Olson has been appointed to its board of directors, effective immediately.
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 22.73% and 33.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67% over the past year to ($0....
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the first quarter ended March 31, 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #dermatologicdisease--Castle today announced its pipeline initiative to develop a genomic test aimed at predicting systemic therapy response.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GenomicTesting--Castle has been selected as the winner of the “Best New Technology Solution for Oncology.”
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ARVO--Castle presented data on its 15-gene expression profile (15-GEP) test, DecisionDx®-UM, at ARVO 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanAcademyofDermatology--Castle today announced its national sponsorship of the American Academy of Dermatology's (AAD) "Skin Cancer, Take a Hike!"
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer tre...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on May 10,...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AADVMX2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatme...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DNANurses--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatmen...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webina...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer...
The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the st...
Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...
Shares of Castle Biosciences (NASDAQ:CSTL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 254.55% year over year to ($0.17), whic...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk
Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Con...
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.
About CSTL
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, ... [Read more...]
| Industry Diagnostics & Research | IPO Date Jul 25, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol CSTL |
Analyst Forecasts
According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 86.83, which is an increase of 25.51% from the latest price.